The post Hyperliquid’s HYPE token flips Cardano’s ADA in market cap appeared on BitcoinEthereumNews.com. Hyperliquid’s native HYPE token has surpassed Cardano’sThe post Hyperliquid’s HYPE token flips Cardano’s ADA in market cap appeared on BitcoinEthereumNews.com. Hyperliquid’s native HYPE token has surpassed Cardano’s

Hyperliquid’s HYPE token flips Cardano’s ADA in market cap

2026/03/19 02:36
Okuma süresi: 3 dk
Bu içerikle ilgili geri bildirim veya endişeleriniz için lütfen [email protected] üzerinden bizimle iletişime geçin.

Hyperliquid’s native HYPE token has surpassed Cardano’s ADA in market capitalization, a milestone that would have sounded absurd six months ago. A decentralized perpetual exchange token just leapfrogged a blockchain that has been in the top ranks since 2017.

The numbers behind the flip

HYPE’s market cap has climbed to roughly $10.2 billion, while ADA sits around $10.0 billion, making the lead extremely narrow. Cardano, a project that raised $62 million in its 2017 ICO and has spent years building out a proof-of-stake ecosystem, now trails a token that did not exist before late 2024, at least for now.

HYPE has been on a tear for months, driven by surging trading volumes on Hyperliquid’s platform and a tokenomics structure that rewards actual usage. The token is trading around $41 to $42 today. ADA, meanwhile, is trading around $0.27 to $0.29 and has struggled to maintain momentum despite broader market tailwinds.

Why Hyperliquid keeps climbing

Hyperliquid operates a decentralized perpetual futures exchange that has become a major venue for onchain derivatives trading. Its order book model, instead of the AMM approach used by many DEXs, gives it a feel closer to centralized exchanges while keeping user custody onchain.

In English, traders get the speed and depth they expect from a CEX, but they keep control of their funds.

The platform continues to post strong activity. CoinGecko shows Hyperliquid spot volume in the hundreds of millions of dollars over the past 24 hours, while HYPE itself logged roughly $491 million in 24 hour trading volume in one live snapshot today.

Cardano, by contrast, has long faced criticism over its slower pace of ecosystem growth. CoinGecko currently ranks Cardano around 25th among blockchains by TVL, underscoring how far it trails faster growing rivals in DeFi traction.

What this means for investors

This flip is not just about two tokens trading places on a leaderboard. It reflects a broader market reassessment of what deserves a premium valuation.

The market is increasingly rewarding protocols that generate real usage and trading activity over those still leaning on long dated ecosystem promises. Hyperliquid is benefiting from that shift right now. That is an inference from its price, market cap, and trading data relative to Cardano’s current position.

That said, HYPE carries its own risks. The ranking gap is thin, and the live data already shows how quickly the lead can change intraday.

There is also concentration risk. Hyperliquid’s rise has been fast, and the platform still has less cycle tested history than Cardano. Cardano, for all its sluggishness, has survived multiple market cycles and still holds a market cap above $10 billion.

For ADA holders, the flip should be a wake up call. Market cap rankings are not permanent. Projects that fail to build competitive DeFi ecosystems and sustained onchain activity can lose ground over time.

For HYPE holders, the question is sustainability. Can Hyperliquid maintain its momentum as competition in onchain derivatives keeps intensifying.

Bottom line, HYPE flipping ADA is one of the clearest signals yet that the crypto market is shifting away from valuing narratives alone and toward valuing usage, liquidity, and revenue potential. Whether the ranking holds tomorrow matters less than what the move represents.

Disclosure: This article was edited by Estefano Gomez. For more information on how we create and review content, see our Editorial Policy.

Source: https://cryptobriefing.com/hype-flips-ada-market-cap/

Piyasa Fırsatı
Hyperliquid Logosu
Hyperliquid Fiyatı(HYPE)
$41.79
$41.79$41.79
+0.50%
USD
Hyperliquid (HYPE) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference

Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference

The post Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference appeared on BitcoinEthereumNews.com. The suitcoiners are in town.  From a low-key, circular podium in the middle of a lavish New York City event hall, Strategy executive chairman Michael Saylor took the mic and opened the Bitcoin Treasuries Unconference event. He joked awkwardly about the orange ties, dresses, caps and other merch to the (mostly male) audience of who’s-who in the bitcoin treasury company world.  Once he got onto the regular beat, it was much of the same: calm and relaxed, speaking freely and with confidence, his keynote was heavy on the metaphors and larger historical stories. Treasury companies are like Rockefeller’s Standard Oil in its early years, Michael Saylor said: We’ve just discovered crude oil and now we’re making sense of the myriad ways in which we can use it — the automobile revolution and jet fuel is still well ahead of us.  Established, trillion-dollar companies not using AI because of “security concerns” make them slow and stupid — just like companies and individuals rejecting digital assets now make them poor and weak.  “I’d like to think that we understood our business five years ago; we didn’t.”  We went from a defensive investment into bitcoin, Saylor said, to opportunistic, to strategic, and finally transformational; “only then did we realize that we were different.” Michael Saylor: You Come Into My Financial History House?! Jokes aside, Michael Saylor is very welcome to the warm waters of our financial past. He acquitted himself honorably by invoking the British Consol — though mispronouncing it, and misdating it to the 1780s; Pelham’s consolidation of debts happened in the 1750s and perpetual government debt existed well before then — and comparing it to the gold standard and the future of bitcoin. He’s right that Strategy’s STRC product in many ways imitates the consols; irredeemable, perpetual debt, issued at par, with…
Paylaş
BitcoinEthereumNews2025/09/18 02:12
Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent?

Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent?

The post Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent? appeared on BitcoinEthereumNews.com. In brief The White House registered aliens.gov
Paylaş
BitcoinEthereumNews2026/03/19 05:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Paylaş
BitcoinEthereumNews2025/09/18 05:26